Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Axsome Thera (AXSM)

Axsome Thera (AXSM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,110,859
  • Shares Outstanding, K 51,153
  • Annual Sales, $ 638,500 K
  • Annual Income, $ -183,170 K
  • EBIT $ -160 M
  • EBITDA $ -150 M
  • 60-Month Beta 0.48
  • Price/Sales 14.33
  • Price/Cash Flow N/A
  • Price/Book 98.88

Options Overview Details

View History
  • Implied Volatility 75.48% (+2.35%)
  • Historical Volatility 34.31%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 75.48% on 04/10/26
  • IV Low 29.12% on 01/22/26
  • Expected Move (DTE 6) 6.54 (3.67%)
  • Put/Call Vol Ratio 0.31
  • Today's Volume 307
  • Volume Avg (30-Day) 995
  • Put/Call OI Ratio 0.66
  • Today's Open Interest 23,617
  • Open Int (30-Day) 21,649
  • Expected Range 171.57 to 184.65

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.85
  • Number of Estimates 7
  • High Estimate $-0.41
  • Low Estimate $-1.27
  • Prior Year $-0.80
  • Growth Rate Est. (year over year) -6.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
152.28 +16.96%
on 03/24/26
181.99 -2.13%
on 04/10/26
+11.77 (+7.08%)
since 03/10/26
3-Month
152.28 +16.96%
on 03/24/26
191.50 -6.99%
on 01/22/26
+8.73 (+5.15%)
since 01/09/26
52-Week
93.95 +89.58%
on 04/11/25
191.50 -6.99%
on 01/22/26
+82.46 (+86.21%)
since 04/10/25

Most Recent Stories

More News
Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4

NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today...

AXSM : 178.11 (-0.44%)
Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions

Axsome obtains exclusive global rights to balipodect, a potentially first-in-class selective phosphodiesterase 10A inhibitor Acquisition further expands Axsome’s industry-leading CNS portfolio with...

AXSM : 178.11 (-0.44%)
Axsome Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced...

AXSM : 178.11 (-0.44%)
Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleepiness Symptoms

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced...

AXSM : 178.11 (-0.44%)
Axsome: Q4 Earnings Snapshot

Axsome: Q4 Earnings Snapshot

AXSM : 178.11 (-0.44%)
Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Total 4Q and full year 2025 net product revenue of $196.0 million and $638.5 million, respectively, representing 65% and 66% year-over-year growth   AUVELITY ® 4Q and full year 2025 net...

AXSM : 178.11 (-0.44%)
Axsome Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced...

AXSM : 178.11 (-0.44%)
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd.

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders,...

AXSM : 178.11 (-0.44%)
Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23

NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced...

AXSM : 178.11 (-0.44%)
MoneyShow Top Picks 2026: Axsome Therapeutics Inc. (AXSM)

Axsome Therapeutics Inc. (AXSM) is a name we started to follow just as the market was going over the falls in early 2025, advises Mike Cintolo, chief investment strategist at Cabot Wealth Network.

AXSM : 178.11 (-0.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies for the management of central nervous system (CNS), disorders for which there are limited treatment options available.

See More

Key Turning Points

3rd Resistance Point 186.06
2nd Resistance Point 184.02
1st Resistance Point 181.07
Last Price 178.11
1st Support Level 176.08
2nd Support Level 174.04
3rd Support Level 171.09

See More

52-Week High 191.50
Last Price 178.11
Fibonacci 61.8% 154.24
Fibonacci 50% 142.73
Fibonacci 38.2% 131.21
52-Week Low 93.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.